Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaoluwa O Okusaga

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Aging and Disease|August 12, 2014
Accelerated aging in schizophrenia patients: the potential role of oxidative stressOlaoluwa O Okusaga
Medical Hypotheses|February 5, 2014
6R-l-erythro-5,6,7,8-tetrahydrobiopterin (BH4): a potential treatment for all symptom domains of schizophreniaOlaoluwa O Okusaga
The Psychiatric Quarterly|August 29, 2014
Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherenceHanjing Emily Wu, Olaoluwa O Okusaga
Behavioral Sciences (Basel, Switzerland)|July 2, 2021
Repetitive Transcranial Magnetic Stimulation: A Potential Treatment for Obesity in Patients with SchizophreniaRamey G Monem, Olaoluwa O Okusaga
Journal of Addiction Medicine|February 21, 2015
Cocaine use in individuals with schizophrenia: impact on doses of discharge antipsychotic medicationsSatyajit Mohite, Ikenna Ngana, Olaoluwa O Okusaga
The Psychiatric Quarterly|October 14, 2018
Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with SchizophreniaTed Boozalis, Sridevi Devaraj, Olaoluwa O Okusaga
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|December 30, 2022
Challenges and Considerations in Treating Negative and Cognitive Symptoms of Schizophrenia Spectrum DisordersAlison Krauss, Jared Bernard, Olaoluwa O Okusaga
The Psychiatric Quarterly|October 2, 2021
Plasma Soluble P-selectin, Interleukin-6 and S100B Protein in Patients with Schizophrenia: a Pilot StudyOmar F Pinjari, Swapan K Dasgupta, Olaoluwa O Okusaga
Psychiatry Research|January 13, 2018
Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disordersHuiqiong Deng, Satyajit Mohite, Robert Suchting, et al.
Journal of Affective Disorders|June 6, 2016
The potential association between obesity and bipolar disorder: A meta-analysisZhuoxian Zhao, Olaoluwa O Okusaga, Joao Quevedo, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Aging and Disease|August 12, 2014
Accelerated aging in schizophrenia patients: the potential role of oxidative stressOlaoluwa O Okusaga
Medical Hypotheses|February 5, 2014
6R-l-erythro-5,6,7,8-tetrahydrobiopterin (BH4): a potential treatment for all symptom domains of schizophreniaOlaoluwa O Okusaga
The Psychiatric Quarterly|August 29, 2014
Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherenceHanjing Emily Wu, Olaoluwa O Okusaga
Behavioral Sciences (Basel, Switzerland)|July 2, 2021
Repetitive Transcranial Magnetic Stimulation: A Potential Treatment for Obesity in Patients with SchizophreniaRamey G Monem, Olaoluwa O Okusaga
Journal of Addiction Medicine|February 21, 2015
Cocaine use in individuals with schizophrenia: impact on doses of discharge antipsychotic medicationsSatyajit Mohite, Ikenna Ngana, Olaoluwa O Okusaga
The Psychiatric Quarterly|October 14, 2018
Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with SchizophreniaTed Boozalis, Sridevi Devaraj, Olaoluwa O Okusaga
Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS|December 30, 2022
Challenges and Considerations in Treating Negative and Cognitive Symptoms of Schizophrenia Spectrum DisordersAlison Krauss, Jared Bernard, Olaoluwa O Okusaga
The Psychiatric Quarterly|October 2, 2021
Plasma Soluble P-selectin, Interleukin-6 and S100B Protein in Patients with Schizophrenia: a Pilot StudyOmar F Pinjari, Swapan K Dasgupta, Olaoluwa O Okusaga
Psychiatry Research|January 13, 2018
Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disordersHuiqiong Deng, Satyajit Mohite, Robert Suchting, et al.
Journal of Affective Disorders|June 6, 2016
The potential association between obesity and bipolar disorder: A meta-analysisZhuoxian Zhao, Olaoluwa O Okusaga, Joao Quevedo, et al.
Pageof 3